Validation teams should not treat the corrigendum as a new GMP obligation today, but they should use it to strengthen readiness planning now. PIC/S confirms that the joint EMA–PIC/S concept paper proposes extending Annex 15: Qualification and Validation to active substance manufacturers and considering ICH Q9(R1) on quality risk management (QRM). The public consultation closed on 9 April 2026, and the corrigendum updates only the initial timetable. For QA, QPs, validation leaders and API sites, the immediate task is a proportionate gap assessment—not premature remediation against requirements that have not yet been finalised.
What PIC/S has confirmed
On 16 July 2026, PIC/S published a notice titled Concept paper on the revision of EU-PIC/S GMP Annex 15 (Qualification and validation) - Corrigendum. PIC/S states that a joint EMA–PIC/S drafting group developed the concept paper and that its aims include extending the scope of Annex 15 to active substance manufacturers and considering the revision of ICH Guideline Q9(R1) on quality risk management.
The notice also confirms two important boundaries. First, comments were collected through the joint public consultation until 9 April 2026. Secondly, following that consultation, only the initial timetable section has been updated. This is therefore a schedule correction, not a published rewrite of the proposed technical direction.
The official concept paper is identified as EMA/INS/GMP/163466/2026, Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and Validation. It was agreed by the EMA GMP/GDP Inspectors Working Group on 30 November 2025 and by PIC/S on 14 January 2026.
Why the proposed scope change matters for API manufacturers
Under the currently published EU GMP Annex 15, the document may be used by active substance manufacturers as supplementary optional guidance, without introducing additional requirements to EudraLex Volume 4, Part II. The concept paper proposes a targeted revision that would make the revised Annex applicable to manufacturers of chemical and biological active substances.
The concept paper links this direction to lessons from inspections of active substance manufacturers, including observations relating to process and product knowledge, investigation of quality issues and contamination-control measures. It says that EU and PIC/S inspectorates would ensure implementation and compliance during regulatory inspections of facilities manufacturing chemical and biological active substances if the revision proceeds as proposed.
Regulatory fact: this is a concept-paper proposal, not a final revised Annex 15. Its intended direction is clear, but the final wording, dates of adoption and implementation arrangements remain subject to the formal drafting, consultation and approval process.
GuideGxP interpretation: API organisations that have historically regarded Annex 15 as useful reference material rather than an explicit inspection baseline should assess their maturity now. The relevant question is not simply whether a validation protocol exists. It is whether the site can demonstrate a coherent qualification and validation system, supported by documented process knowledge, lifecycle QRM, effective change control and oversight of outsourced work.
Likely operational focus areas
The concept paper identifies selected areas where Annex 15 could be extended or clarified for active substance manufacturing. These proposed areas offer a practical structure for an internal readiness review.
| Proposed area | What the concept paper indicates | Practical readiness question |
|---|---|---|
| Qualification and validation governance | Extension of the Validation Master File concept, qualification and validation policy, and change control. | Can the site show a current, risk-based overview of systems, processes, responsibilities, status and planned work? |
| Outsourced activities | Greater expectations for validation performed by third-party contractors. | Do technical agreements, supplier oversight and approval controls establish who owns protocols, deviations, raw data and conclusions? |
| Qualification lifecycle | Application of URS, FAT/SAT, DQ, IQ, OQ and PQ concepts to API manufacturing. | Are lifecycle decisions traceable from user need and design through acceptance testing, commissioning, qualification and routine use? |
| Process validation | Emphasis on robust development, concurrent validation, supplier qualification, recovery of materials and solvents, continuous process verification and periodic review. | Is the validation strategy visibly connected to process knowledge, CQAs, CPPs, recovery steps and ongoing verification data? |
| Transport | Additional guidance on verifying transportation, extending Part II Chapter 10. | Is transport risk assessed against the API’s quality attributes, route conditions, packaging and handover controls? |
| QRM | Targeted alignment with ICH Q9(R1), including risk review activities supporting qualification and validation. | Can the site show how risk assessments are reviewed when knowledge, trends, deviations or changes alter the original assumptions? |
QRM is likely to be tested through evidence, not terminology
The concept paper says that QRM in the design and validation or qualification of monitoring systems will be underlined, with risk-review activities supporting validation and qualification. It also proposes emphasis on QRM in the context of traditional processes.
For senior GMP professionals, the significant issue is traceability. A risk assessment should not operate as a one-off approval attachment. It should connect the intended use, criticality rationale, acceptance criteria, sampling strategy, deviation handling, change control and periodic review. Where a site uses risk to reduce testing, narrow qualification scope or justify reliance on supplier evidence, the scientific and procedural basis must remain inspectable.
That expectation is consistent with the current Annex 15 principle that the scope and extent of qualification and validation should be based on a justified and documented risk assessment, repeated where needed as knowledge develops. The proposed revision may make the application of that lifecycle logic more explicit for API operations.
How to plan around the corrigendum
The official PIC/S notice says the post-consultation update concerns the timetable only. Teams should therefore avoid locking a large remediation programme to dates copied from an earlier concept-paper version. Confirm the current timetable directly from the corrigendum before setting governance milestones, supplier commitments or capital-project dependencies.
At the same time, waiting for the final text is rarely the most efficient response. Many of the proposed themes—clear validation governance, documented process knowledge, appropriate investigation, transport understanding and risk-based lifecycle control—are already familiar GMP disciplines. Readiness activity can concentrate on evidence quality and consistency while preserving flexibility for final requirements.
Practical readiness checklist
- Establish ownership. Assign a cross-functional lead group spanning QA, validation, engineering, manufacturing, supply chain and regulatory affairs.
- Map Annex 15 interfaces. Compare the site’s API quality system with EudraLex Volume 4, Part II and the current Annex 15 principles that the concept paper proposes to extend.
- Review the validation governance model. Check whether the Validation Master Plan or equivalent clearly identifies scope, status, roles, risk management, deviations, change control and periodic review.
- Test outsourced-validation controls. Sample contractor-led protocols and reports for approval, data access, deviation investigation, acceptance-criteria ownership and final conclusions.
- Trace process knowledge into protocols. Select high-risk or complex API processes and verify that CQAs, CPPs, recovery operations, sampling and acceptance criteria are scientifically linked.
- Challenge QRM effectiveness. Review whether risk assessments are updated after process changes, investigations, recurring trends or new monitoring data.
- Assess transport verification. Identify APIs where transport conditions, packaging configuration, route variability or storage excursions could affect quality.
- Maintain a decision log. Record assumptions, identified gaps, interim controls and items deliberately deferred pending the draft guideline.
What not to conclude from this update
- The corrigendum does not itself make Annex 15 mandatory for API manufacturers.
- The PIC/S notice does not announce a final revised Annex 15.
- The technical content has not been described by PIC/S as newly changed; PIC/S says only the initial timetable was updated after consultation.
- Organisations should not assume that every current Annex 15 practice will be transferred unchanged into the final text for active substance manufacturing.
FAQ
Is the revised Annex 15 already in force?
No. The July 2026 PIC/S item concerns a corrigendum to a concept paper. It does not publish a final revised Annex 15 or a new enforceable implementation date.
Will Annex 15 apply to all API manufacturers?
The concept paper proposes extending the Annex to manufacturers of chemical and biological active substances. The final scope will depend on the completed revision and approval process.
What should a QP or QA leader do now?
Confirm the corrected timetable from the official corrigendum, sponsor a focused readiness assessment and prioritise gaps that already represent weak GMP evidence or weak lifecycle control.
Does ICH Q9(R1) require a separate validation system?
No separate system is indicated. The proposal is to consider ICH Q9(R1) through targeted Annex 15 revisions, particularly by reinforcing risk-based qualification, validation and risk-review practices.
Primary sources
- PIC/S News: Concept paper on the revision of EU-PIC/S GMP Annex 15 (Qualification and validation) - Corrigendum, 16 July 2026.
- EMA/INS/GMP/163466/2026: Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and Validation.
- European Commission: EudraLex Volume 4 - Good Manufacturing Practice guidelines.
- EudraLex Volume 4: Annex 15: Qualification and Validation.
Keep the regulatory signal practical. Subscribe to The Pragmatic GMP for focused GMP analysis, implementation insight and Radar updates.
